Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

OBJECTIVES: To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis. METHODS: Data from seven trials were integrated (NCT01888874, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700 and NCT03...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ANNALS OF THE RHEUMATIC DISEASES 2024-08, Vol.83 (9)
Hauptverfasser:	Burmester, Gerd R, Gottenberg, Jacques-Eric, Caporali, Roberto, Winthrop, Kevin L, Tanaka, Yoshiya, Omoruyi, Edmund V. Ekoka, Rajendran, Vijay, Van Hoek, Paul, Van Beneden, Katrien, Takeuchi, Tsutomu, Westhovens, Rene, Aletaha, Daniel
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!